Company intelligence / Profile preview

STARS

Munich, Bavaria, Germany

Ownership: Private
Development stage: Other

Overview

STARS Therapeutics is a preclinical-stage biotechnology company focused on developing next-generation precision medicines for oncology. The company leverages its proprietary STARS platform to identify and exploit synthetic lethal interactions within DNA damage response (DDR) pathways. By targeting specific vulnerabilities in cancer cells, STARS aims to develop highly selective small molecule inhibitors that overcome resistance to current therapies. Their pipeline primarily focuses on targeting key kinases involved in DNA repair, such as DNA-PK and ATM, to treat various solid tumors.

Therapeutic areas: Oncology
Modalities: Small moleculeProtein
Industry: Biotech

Beyond the preview

Go deeper on STARS.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on STARS.

Explore the full profile